# A Long Term Safety and Efficacy Study of Fabrazyme Replacement Therapy in Japanese Patients With Fabry Disease.

> **NCT00233870** · — · COMPLETED · sponsor: **Genzyme, a Sanofi Company** · enrollment: 405 (actual)

## Conditions studied

- Fabry Disease

## Interventions

- **DRUG:** Agalsidase beta (recombinant form)

## Key facts

- **NCT ID:** NCT00233870
- **Lead sponsor:** Genzyme, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2004-06
- **Primary completion:** 2011-03
- **Final completion:** 2011-03
- **Target enrollment:** 405 (ACTUAL)
- **Last updated:** 2015-05-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00233870

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00233870, "A Long Term Safety and Efficacy Study of Fabrazyme Replacement Therapy in Japanese Patients With Fabry Disease.". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT00233870. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*